Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Evaluation of 18F-AV-1451
NCT02278367Phase 2Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Dec 2014
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of flortaucipir in Alzheimer's disease (AD), traumatic brain injury (TBI), major depressive disorder (MDD), sponsored by Avid Radiopharmaceuticals. Started Dec 2014; status: completed.
02
Drugs
flortaucipir
03
Conditions
Alzheimer's disease (AD)traumatic brain injury (TBI)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02278367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02278367.